期刊
MODERN PATHOLOGY
卷 25, 期 3, 页码 347-369出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/modpathol.2011.215
关键词
lung adenocarcinoma; EML4-ALK rearrangement; epidermal growth factor receptor (EGFR); KRAS mutation; molecular classification; personalized medicine; targeted therapy
类别
The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR) mutated or EML4-ALK rearrangement-positive tumors are sensitive to tyrosine kinase inhibitors. Both primary and acquired resistance in a significant number of those patients to these therapies remains a major clinical problem. The specific molecular mechanisms associated with tyrosine kinase inhibitor resistance are not fully understood. Clinicopathological observations suggest that molecular alterations involving so-called 'driver mutations' could be used as markers that aid in the selection of patients most likely to benefit from targeted therapies. In this review, we summarize recent developments involving the specific molecular mechanisms and markers that have been associated with primary and acquired resistance to EGFR-targeted therapy in lung adenocarcinomas. Understanding these mechanisms may provide new treatment avenues and improve current treatment algorithms. Modern Pathology (2012) 25, 347-369; doi:10.1038/modpathol.2011.215; published online 27 January 2012
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据